ABSTRACT
Proteins are an im portant drug class because of their potential to treat a wide range of conditions. Compared to small drug entities, protein therapeutics are highly specific in their action, and are expected to be less toxic than synthetically derived molecules as well as to behave more predictably in vivo [1]. They thus represent a significant potential market. The global therapeutic proteins market has been estim ated to have been worth $93 billion in 2 0 1 0 and has been forecast to grow to $141.5 billion by 20 1 7 [2].
